Author
The author works as a Correspondent with BW Businessworld
Alembic's Profit After Tax (PAT) was recorded at Rs 121 crores in Q1FY24 against a net loss of Rs 86 crores in the same quarter last year whereas the profits dipped by 21 per cent quarter on quarter (QoQ) compared with Rs 153 crores recorded in the March quarter
Read More
Sun Pharma's Profit After Tax (PAT) fell by 1.8 per cent YoY to Rs 2,022 crores against Rs 2,060 crores in the corresponding quarter of the previous year.
Read More
According to the National Cancer Registry Programme, India registered 14.61 lakh cancer cases in 2022 compared to 13.92 lakh cases in 2020. In 2022 over 54 per cent of people diagnosed with cancer succumbed to the disease with total deaths around 8.08 lakh
Read More
On Friday, an industry body of Indian medical device manufacturers, AiMeD expressed its gravest concerns over an Official Memorandum (OM) issued by the government to its various Ministries enabling the import of pre-owned or pre-used and refurbished medical devices in India from MNCs
Read More
Cipla Limited, the Indian pharmaceutical major headquartered in Mumbai has reported its earnings for the quarter that ended on 30 June 2023, the Indian pharma giant has registered a rise of 18 per cent in its consolidated revenue to be recorded at Rs 6,465 crores in the Quarter One of Financial Year 2024 (Q1FY24) up from Rs 5,478 crores in the corresponding quarter last year
Read More
While highlighting the rarity of the case Dr Subramania Iyer, HOD, Head and Neck Surgery, Amrita Hospital said that in his 30 years of experience, this case is one of a kind and it's possible that he will not encounter a similar case again in his lifetime
Read More
Startups and tech companies across industries are being valued today at mountain-high valuations, with investors sprinkling the dry powder and founders aiming for volumes, scale and consolidation and not minding the losses. But the industry today is also not new to certain post-listing debacles of tech companies and a recent valuation turnaround of a health-tech company PharmEasy lowering its valuations by 90 per cent to fund its debt
Read More
While The GST Council’s decision was well received across the spectrum, pharmaceutical companies, industry bodies and patient advocacy groups have argued that the exemption should be applicable to all rare disease drugs and should not be only restricted when imported for personal use as this can pose multiple challenges for patients
Read More
In India, the Danish drugmaker Novo Nordisk is the market leader and presently claims around 60 per cent of the country’s insulin supply. Speaking to BW Businessworld in an exclusive interaction, John C. Dawber, CVP and MD, Global Business Services talks about the company’s GLP1 growth story, the market of obesity drugs and their safety profile, building capacities and the company's future ambitions in India
Read More
Experts believe with access to health rising post-pandemic in India, the carbon footprint is also slated to rise simultaneously. The report by HWH also affirms this by showing a strong correlation between a nation’s health spending and its carbon footprint. India at present is witnessing a huge capacity build in the healthcare sector with the healthcare providers expanding their bed capacities on account of increasing bed occupancies in the hospitals
Read More
